← Leaderboards
Gregory James Mertz
University Of New Mexico
$6,558,066
Attributed
$6,558,066
Total exposure
15
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$15,307,342 · 16
By mechanism
U19$9,904,569 · 5
U01$2,738,560 · 1
M01$1,474,159 · 8
D43$1,190,054 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of New Mexico
Same institution · by research overlap
- Brian L. Hjelle$5,689,189
- Terry Yates$100,477
- Frederick Kester$100,477
- Tione Buranda$2,191,935
- Richard S Larson$48,778,223
Others in their field
Top investigators on “Hantavirus”
- Kartik Chandran · Albert Einstein College Of Medicine$32,338,382
- Alessandro Sette · La Jolla Institute For Immunology$22,115,370
- Erich R. Mackow · State University New York Stony Brook$9,924,418
- Jay Williams Hooper · Geneva Foundation$7,880,772
- Robert H Carnahan · Vanderbilt University$7,023,024
- Osmer Marjorie · Geneva Foundation$6,675,924
Research focus
HantavirusClinical ResearchDisease OutbreaksPersonsAndes VirusCardiopulmonaryVirus DiseasesReportingSyndromeChileClinical TrialsHuman SubjectCooperative StudyUnited States National Institutes Of HealthUrineVaccinesFecesCategoriesFundingGrantResearch PersonnelRodentAreaSouth America
Grant awards (50)
Andes virus transmission and pathogenesis in Chile$549,349
U01 · FY2014 · AI · contact PI
Andes virus transmission and pathogenesis in Chile$516,389
U01 · FY2013 · AI · contact PI
Andes virus transmission and pathogenesis in Chile$549,350
U01 · FY2012 · AI · contact PI
Andes virus transmission and pathogenesis in Chile$548,213
U01 · FY2011 · AI · contact PI
Andes virus transmission and pathogenesis in Chile$575,259
U01 · FY2010 · AI · contact PI
Training in Hantavirus Ecology, Virology & Clinical Investigation in the Americas$123,877
D43 · FY2010 · TW · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLAC$4,843
M01 · FY2010 · RR · contact PI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA$951,433
U19 · FY2009 · AI · contact PI
Treatment and Prevention of HCPS$165,148
U19 · FY2009 · AI · contact PI
Training in Hantavirus Ecology, Virology & Clinical Investigation in the Americas$123,856
D43 · FY2009 · TW · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLAC$74,321
M01 · FY2009 · RR · contact PI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA$941,456
U19 · FY2008 · AI · contact PI
CLINICAL TRIAL: A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS$173,959
M01 · FY2008 · RR · contact PI
Treatment and Prevention of HCPS$162,073
U19 · FY2008 · AI · contact PI
Training in Hantavirus Ecology, Virology & Clinical Investigation in the Americas$141,717
D43 · FY2008 · TW · contact PI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA$931,499
U19 · FY2007 · AI · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLAC$250,960
M01 · FY2007 · RR · contact PI
Treatment and Prevention of HCPS$164,796
U19 · FY2007 · AI · contact PI
Training in Hantavirus Ecology, Virology & Clinical Investigation in the Americas$124,205
D43 · FY2007 · TW · contact PI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA$934,697
U19 · FY2006 · AI · contact PI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLAC$237,982
M01 · FY2006 · RR · contact PI
Training in Hantavirus Ecology, Virology & Clinical Investigation in the Americas$126,400
D43 · FY2006 · TW · contact PI
Treatment and Prevention of HCPS$82,825
U19 · FY2006 · AI · contact PI
PASSIVE IMMUNOTHERAPY OF HANTAVIRUS CARDIOPULMONARY SYNDROME$21,804
M01 · FY2006 · RR · contact PI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE AND PANAMA$895,759
U19 · FY2005 · AI
Administrative/Clinical Core$277,954
U19 · FY2005 · AI
A DOUBLE-BLIND, RANDOMIZED, CONTROLLED PHASE III STUDY TO ASSESS THE PROPHYLAC$123,033
M01 · FY2005 · RR
Treatment and Prevention of HCPS$101,542
U19 · FY2005 · AI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE$1,005,735
U19 · FY2004 · AI
FOGARTY-ACTIONS IN BUILDING CAPACITY IN SUPPORT OF ICIDR$100,000
D43 · FY2004 · TW
Postdoctoral Training in the Hantavirus Project Ecology$49,999
D43 · FY2004 · TW
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE$686,120
U19 · FY2003 · AI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE$300,000
U19 · FY2003 · AI
FOGARTY-ACTIONS IN BUILDING CAPACITY IN SUPPORT OF ICIDR$100,000
D43 · FY2003 · TW
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE$628,931
U19 · FY2002 · AI
CONTROLLED TRIAL OF INTRAVENOUS RIBAVIRIN VERSUS PLACEBO FOR HANTAVIRUS$282,412
M01 · FY2002 · RR
FOGARTY-ACTIONS IN BUILDING CAPACITY IN SUPPORT OF ICIDR$100,000
D43 · FY2002 · TW
TREATMENT OF HANTAVIRAL CARDIOPULMONARY SYNDROME$0
U19 · FY2002 · AI
CORE--CLINICAL$0
U19 · FY2002 · AI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE$718,307
U19 · FY2001 · AI
CONTROLLED TRIAL OF INTRAVENOUS RIBAVIRIN VERSUS PLACEBO FOR HANTAVIRUS$282,412
M01 · FY2001 · RR
FOGARTY-ACTIONS IN BUILDING CAPACITY IN SUPPORT OF ICIDR$100,000
D43 · FY2001 · TW
TREATMENT OF HANTAVIRAL CARDIOPULMONARY SYNDROME$0
U19 · FY2001 · AI
CORE--CLINICAL$0
U19 · FY2001 · AI
HANTAVIRUS ECOLOGY AND DISEASE IN CHILE$755,339
U19 · FY2000 · AI
CORE--CLINICAL$100,478
U19 · FY2000 · AI
TREATMENT OF HANTAVIRAL CARDIOPULMONARY SYNDROME$100,477
U19 · FY2000 · AI
FOGARTY-ACTIONS IN BUILDING CAPACITY IN SUPPORT OF ICIDR$100,000
D43 · FY2000 · TW
CONTROLLED TRIAL OF INTRAVENOUS RIBAVIRIN VERSUS PLACEBO FOR HANTAVIRUS$22,433
M01 · FY2000 · RR
CONTROLLED TRIAL OF INTRAVENOUS RIBAVIRIN VERSUS PLACEBO FOR HANTAVIRUS$0
M01 · FY2000 · RR